Wire · opportunities
Medtronic Presents New Nocturia Data for the AltavivaTM Device, Announces National ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 6 October 2026 · Fusion42 review
Medtronic presented new 24-month clinical data showing sustained nocturia episode reductions with the AltavivaTM tibial neuromodulation device, following its FDA approval in 2025 for urge urinary incontinence treatment. The company also named a national principal investigator for a post-approval study and formed a partnership with the American Urogynecologic Society to raise patient awareness about pelvic floor disorders.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You should track real-world data opportunities now that Medtronic's Altaviva device shows durable benefits beyond initial approval. Patient education partnerships are opening doors to wider treatment adoption and new referral pathways.
◆ Coverage
1 source · 6 Oct 2026
◆ Related on Wire
◆ Topics